Apellis Pharmaceuticals Inc

NASDAQ:APLS   4:00:00 PM EDT
46.88
-2.50 (-5.06%)
6:23:53 PM EDT: $46.53 -0.35 (-0.75%)
Products

Apellis Announces FDA Acceptance Of NDA Amendment And New PDUFA Date For Eye Disease Drug

Published: 11/18/2022 12:18 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (ga).
Apellis Pharma - FDA Has Accepted Co's Unsolicited Major Amendment NDA for Intravitreal Pegcetacoplan.
Apellis Pharmaceuticals Inc - PDUFA Goal Date is February 26, 2023.
Apellis Pharmaceuticals Inc - FDA Also Restated That They Do Not Plan to Hold an Advisory Committee Meeting to Discuss Application.